Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

To join a study like this, certain conditions must be met to ensure the research is safe and accurate. For instance, you would need to have been diagnosed with a specific type of advanced oesophageal cancer that has spread. You must also be well enough generally, meaning your blood pressure is controlled and your organs (like your liver and kidneys) are working properly.

There are also reasons why someone might not be able to join. For example, if you've already had treatment for advanced oesophageal cancer, or if your cancer is too close to major organs like your main artery (aorta) or windpipe (trachea), you wouldn't be able to take part. Also, if there are risks of bleeding in your gut or severe bleeding from your tumours, or if you have uncontrollable fluid around your lungs or heart, you'd be excluded. The study also had specific rules about contraception for both men and women to prevent pregnancy during and after the treatment period.

All participants needed to be at least 18 years old. These rules are put in place to protect the people taking part and to make sure the results of the study are reliable.

This study was conducted in two parts. The first part, a 'safety run-in', involved a small group of patients receiving specific drug combinations (pembrolizumab, lenvatinib, plus either cisplatin and 5-FU, or paclitaxel and cisplatin). This part was to check for any severe side effects and how well people tolerated the drugs. The main study (Part 2) involved more patients, where some received pembrolizumab, lenvatinib, and chemotherapy, while others received pembrolizumab and chemotherapy.

Patients would have regular check-ups, assessments, and scans to monitor their health, the size of their tumours, and any side effects. The medications would be given according to a set schedule. Patients would stay on the treatment as long as it was helping and they weren't experiencing unmanageable side effects. Typically, studies like this involve multiple hospital visits for infusions, blood tests, and scans over many months. However, this specific study has now stopped accepting new participants and is closing down, meaning no new patients are entering, and further follow-up or treatment for existing participants within this specific trial is no longer being offered.